R

Rhythm Pharmaceuticals

Commercializes MC4R-targeted therapies for rare obesity

IT Business Analyst - Clinical & Biostatistics

Full-Time
$90k - $135k/yr+ Discretionary annual bonus + Restricted stock units
Senior
Bachelor's
Boston, MA, USA
HybridHybrid role requiring in-office attendance in coordination with the department and business needs.
Business & StrategyBusiness Analysis

About the job

Requirements
  • A bachelor's degree in information systems, computer science, life sciences, or a related field, or equivalent practical experience.
  • At least 5 years of progressively responsible business analysis, product ownership, application management, or technology delivery experience in a life-sciences or biopharmaceutical environment.
  • Experience supporting systems and processes used by clinical development, clinical operations, clinical data management, biostatistics, or statistical programming in a regulated life-sciences environment.
  • Working knowledge of the clinical study lifecycle, including study startup, conduct, monitoring, data acquisition, data cleaning and review, reconciliation, database lock, closeout, and archival.
  • Strong elicitation, process mapping, requirements, testing, documentation, analytical, facilitation, and stakeholder-management skills.
  • Ability to manage multiple priorities, work independently within established direction, influence outcomes, and contribute hands-on when needed.
  • Written and verbal communication skills, with a customer service, technology advisory, and partnership mindset.
  • Hands-on implementation or support of EDC, clinical data repository, eTMF, CTMS, or statistical computing platforms.
  • Knowledge of GxP computerized system validation, 21 CFR Part 11, electronic records controls, audit readiness, and data integrity principles.
  • A relevant business analysis, product ownership, project management, Agile, Veeva, or life-sciences technology certification.
Responsibilities
  • Build partnerships with Clinical Development, Clinical Operations, Clinical Data Management, Biostatistics, and Statistical Programming to understand business priorities, challenges, risks, and opportunities, and serve as a technology subject-matter resource for assigned systems and processes.
  • Conduct discovery through interviews, workshops, document analysis, task analysis, and data-flow reviews; translate needs into requirements, user stories, acceptance criteria, process maps, data mappings, and traceability artifacts.
  • Map end-to-end clinical data flows from source acquisition through data review, reconciliation, standardization, analysis, reporting, and regulatory submission, and partner with business process owners to support future-state process design.
  • Partner with stakeholders and the Director, IT Business Partner R&D, to assess business demand, enhancements, and project opportunities and provide input into prioritization based on business value, risk, urgency, and available resources.
  • Partner with study teams to anticipate and support technology and data needs across study startup, conduct, database lock, closeout, and submission readiness.
  • Support clinical trial systems and processes, including EDC, eTMF, CTMS or trial tracking, eCOA or ePRO, IRT or randomization, laboratory and imaging data, clinical data repositories, and analytics.
  • Support statistical computing capabilities and workflows, including validated workspaces, controlled code and metadata, data transfers, SDTM and ADaM production, TLF generation, outputs, archival, and reproducibility.
  • Partner with business, vendors, and technical teams on platform configuration, study setup, integrations, secure transfers, APIs, data ingestion, reconciliation, dashboards, and downstream analytics readiness.
  • Develop and maintain business cases, scope, requirements, operating models, RACI, process flows, data lineage, governance materials, support procedures, and roadmap inputs.
  • Lead or coordinate test strategy, scripts, user acceptance testing, defect triage, validation evidence, release readiness, training, adoption, and transition to steady-state support for assigned initiatives.
  • Support clinical data standards, metadata governance, and cross-study consistency in partnership with Clinical Data Management, Biostatistics, Statistical Programming, and other process owners.
  • Ensure projects and changes follow applicable IT lifecycle, change control, validation, security, privacy, data integrity, records management, and GxP procedures.
  • Coordinate application support, issue resolution, root-cause analysis, enhancement intake, release planning, and vendor performance for assigned clinical and biostatistics systems.
  • Communicate dependencies, status, decisions, and risks to cross-functional teams and senior leadership.
  • Contribute to the R&D technology roadmap and support the evaluation of automation, analytics, metadata-driven standards, and responsible AI opportunities across clinical data and statistical workflows.
Desired Qualifications
  • Experience implementing or supporting one or more of the following: EDC, clinical data repositories, eTMF, CTMS, eCOA/ePRO, IRT/RTSM, or validated statistical computing platforms.
  • Experience with platforms such as Medidata Rave or comparable EDC and eClinical Solutions elluminate or comparable clinical data repository and review platform.
  • Working knowledge of clinical data management workflows, external data transfers, edit checks, coding, issue management, and oversight of CRO or technology vendors.
  • Working knowledge of biostatistics and statistical programming workflows from analysis specifications through standardized datasets, tables, listings, figures, quality control, and submission deliverables.
  • Working knowledge of CDISC SDTM and ADaM, TLF workflows, SAS, clinical data transfers, and database-lock processes.
  • Experience with clinical data transfers using SFTP or APIs, integration and ETL patterns, metadata repositories, reporting tools, Microsoft 365, SharePoint, and Smartsheet.
  • Experience managing CROs, SaaS vendors, implementation partners, support SLAs, releases, and enhancement backlogs.

About the company

R

Rhythm Pharmaceuticals

View
Website

Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2008

Get referred to Rhythm Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 product revenue hit $71.3 million, up 19% sequentially.
  • More than 400 acquired-HO start forms came from roughly 300 prescribers by June 30, 2026.
  • AJ Joshi became chief medical officer on August 17, 2026, strengthening late-stage execution.

What critics are saying

  • Rhythm depends on IMCIVREE; August 2026 revenue still came entirely from one drug.
  • RM-718 and bivamelagon must succeed after 2026 data; failure leaves no next growth engine.
  • Hypothalamic obesity launches in Japan and Europe need reimbursement speed; delays hit 2027 demand.

What makes Rhythm Pharmaceuticals unique

  • Rhythm owns the only approved MC4R franchise for rare genetic obesity, built since 2008.
  • IMCIVREE won Japan MHLW approval on August 24, 2026, extending global rare-obesity reach.
  • Rhythm published a Bardet-Biedl diagnostic algorithm, improving patient identification for prescribers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options
  • Performance Bonus
  • Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

8%

2 year growth

2%
Yahoo Finance
Oct 13th, 2026
Rhythm launches IMCIVREE in Japan, the first approved therapy for acquired hypothalamic obesity

Rhythm Pharmaceuticals has launched IMCIVREE (setmelanotide) in Japan to treat acquired hypothalamic obesity. It is the first approved therapy for the condition in the country, and it is now on Japan's National Health Insurance drug price list. Japan's Ministry of Health, Labour and Welfare approved the drug in August. The approval rested on the Phase 3 TRANSCEND trial of 142 patients, which met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm, based in Boston, estimates that 5,000 to 8,000 people in Japan live with the condition. "This launch marks an important advancement for people living with acquired HO in Japan," said Yann Mazabraud, executive vice president and head of international at Rhythm.

Yahoo Finance
Sep 12th, 2026
Druckenmiller's fund buys $22.6M stake in rare obesity treatment maker Rhythm Pharmaceuticals

Stanley Druckenmiller's Duquesne Family Office disclosed new positions in over 40 stocks in its second quarter 13F filing. Notable healthcare investments included 203,618 shares of Rhythm Pharmaceuticals worth $22.6 million and 356,600 shares of Definium Therapeutics worth $16.8 million. Rhythm Pharmaceuticals develops treatments for hypothalamic obesity, currently the only approved drug for this condition. The company estimates approximately 10,000 US patients have acquired hypothalamic obesity, with similar numbers in Europe and 5,000 to 8,000 in Japan. Second-quarter revenue increased 47% year over year, whilst US revenue jumped 38% sequentially. The company remains unprofitable despite revenue growth and held $330.9 million in cash at quarter end, expected to fund operations for at least 24 months.

Yahoo Finance
Aug 24th, 2026
Japan approves Imcivree for acquired hypothalamic obesity, launch expected by end of 2026

Rhythm Pharmaceuticals has received approval from Japan's Ministry of Health, Labour and Welfare for IMCIVREE (setmelanotide) to treat patients with acquired hypothalamic obesity (HO). This marks the first therapy approved in Japan for this condition. The approval was supported by the Phase 3 TRANSCEND trial involving 142 patients, including a Japanese cohort. The study met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm estimates 5,000 to 8,000 people are living with acquired HO in Japan. The company expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Acquired HO is characterised by accelerated weight gain following hypothalamic injury, often resulting from craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumours.

Yahoo Finance
Aug 17th, 2026
Rhythm Pharmaceuticals appoints Manher Joshi as chief medical officer

Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.

Associated Press
Aug 11th, 2026
Rhythm Pharmaceuticals' IMCIVREE receives UK approval for acquired hypothalamic obesity treatment

Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.